{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:37:03Z","timestamp":1792417023383,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>TERT promoter mutations are not infrequently encountered in thyroid carcinomas; however, it is unclear if additional molecular alterations may play a role in determining tumor behavior.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fine-needle aspiration (FNA) specimens from 32 patients with TERT promoter mutations detected by ThyroSeq v3 from 4 institutions were included in the study. FNA diagnoses, molecular results, and surgical follow-up were retrospectively reviewed and analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 5 benign and 27 malignant neoplasms, including 7 high-grade thyroid carcinomas (HGCs) on histopathologic follow-up. Of 4 cases with an isolated TERT mutation, 3 (75%) cases were malignant. Of 17 cases harboring a co-occurring TERT mutation with 1 additional molecular alteration, 13 (76%) displayed malignancy on histopathologic follow-up. All 11 cases with TERT mutations plus 2 or more additional molecular alterations were malignant on follow-up. Furthermore, HGC was not seen in cases with an isolated TERT mutation, while 80% of cases harboring TERT mutations plus 3 additional molecular alterations showed HGC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TERT promoter mutations are commonly associated with malignancy, particularly HGCs, when multiple co-occurring molecular alterations are present. However, TERT promoter mutations may occasionally be detected in benign thyroid neoplasms when encountered in isolation or with fewer than 2 additional molecular alterations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqae117","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T20:09:03Z","timestamp":1725912543000},"page":"251-257","source":"Crossref","is-referenced-by-count":4,"title":["<i>TERT<\/i> promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up"],"prefix":"10.1093","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-1146","authenticated-orcid":false,"given":"Rita","family":"Abi-Raad","sequence":"first","affiliation":[{"name":"Department of Pathology, Yale University School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Emory University Hospital , Atlanta, GA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8005-4399","authenticated-orcid":false,"given":"Fei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York University Langone Health , New York, NY ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Antony","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale Cancer Center, Yale University School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Emory University Hospital , Atlanta, GA ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Simsir","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York University Langone Health , New York, NY ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Dartmouth Health and Geisel School of Medicine at Dartmouth , Lebanon, NH ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar C","family":"Brandler","sequence":"additional","affiliation":[{"name":"Department of Pathology, New York University Langone Health , New York, NY ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Cai","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale University School of Medicine , New Haven, CT ,","place":["US"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"17","key":"2025021323425438200_CIT0001","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1016\/j.febslet.2010.05.026","article-title":"Telomeres and telomerase in normal and cancer stem cells","volume":"584","author":"Shay","year":"2010","journal-title":"FEBS Lett."},{"issue":"5","key":"2025021323425438200_CIT0002","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0959-8049(97)00062-2","article-title":"A survey of telomerase activity in human cancer","volume":"33","author":"Shay","year":"1997","journal-title":"Eur J Cancer."},{"issue":"5","key":"2025021323425438200_CIT0003","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"issue":"5349","key":"2025021323425438200_CIT0004","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1126\/science.279.5349.349","article-title":"Extension of life-span by introduction of telomerase into normal human cells","volume":"279","author":"Bodnar","year":"1998","journal-title":"Science."},{"issue":"29","key":"2025021323425438200_CIT0005","doi-asserted-by":"publisher","first-page":"e11548","DOI":"10.1097\/MD.0000000000011548","article-title":"The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer","volume":"97","author":"Jin","year":"2018","journal-title":"Medicine (Baltim)."},{"issue":"6122","key":"2025021323425438200_CIT0006","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science."},{"issue":"15","key":"2025021323425438200_CIT0007","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2025021323425438200_CIT0008","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2025021323425438200_CIT0009","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"2025021323425438200_CIT0010","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/PAP.0000000000000380","article-title":"Advances in thyroid pathology: high grade follicular cell-derived thyroid carcinoma and anaplastic thyroid carcinoma","volume":"30","author":"Xu","year":"2023","journal-title":"Adv Anat Pathol."},{"issue":"11","key":"2025021323425438200_CIT0011","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/ERC-22-0151","article-title":"Prognostic of recurrence and survival in poorly differentiated thyroid cancer","volume":"29","author":"Hescot","year":"2022","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2025021323425438200_CIT0012","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/cen.14316","article-title":"The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis","volume":"94","author":"Chen","year":"2021","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2025021323425438200_CIT0013","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cen.13413","article-title":"Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma\u2014a meta-analysis","volume":"87","author":"Vuong","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"2025021323425438200_CIT0014","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/cncr.33421","article-title":"Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: a matched case-control study","volume":"127","author":"Yip","year":"2021","journal-title":"Cancer."},{"issue":"1","key":"2025021323425438200_CIT0015","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1038\/s41598-020-64635-8","article-title":"Molecular profile of locally aggressive well differentiated thyroid cancers","volume":"10","author":"Mady","year":"2020","journal-title":"Sci Rep."},{"issue":"2","key":"2025021323425438200_CIT0016","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/thy.2018.0339","article-title":"Impact of mutation density and heterogeneity on papillary thyroid cancer clinical features and remission probability","volume":"29","author":"Colombo","year":"2019","journal-title":"Thyroid."},{"issue":"1","key":"2025021323425438200_CIT0017","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cen.14728","article-title":"Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma","volume":"97","author":"Na","year":"2022","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2025021323425438200_CIT0018","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology."},{"issue":"6","key":"2025021323425438200_CIT0019","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2025021323425438200_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-28046-7_1","article-title":"Overview of diagnostic terminology and reporting","volume-title":"The Bethesda System for Reporting Thyroid Cytopathology.","author":"Baloch","year":"2023","edition":"3"},{"issue":"8","key":"2025021323425438200_CIT0021","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/cncr.31245","article-title":"Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules","volume":"124","author":"Nikiforova","year":"2018","journal-title":"Cancer."},{"key":"2025021323425438200_CIT0022","volume-title":"Endocrine and Neuroendocrine Tumours.","author":"The WHO Classification of Tumours Editorial Board","year":"2024","edition":"5"},{"issue":"6","key":"2025021323425438200_CIT0023","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/cncr.21739","article-title":"Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients","volume":"106","author":"Hiltzik","year":"2006","journal-title":"Cancer."},{"issue":"8","key":"2025021323425438200_CIT0024","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","article-title":"Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"2025021323425438200_CIT0025","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.gde.2020.02.001","article-title":"TERT promoter mutations and telomeres during tumorigenesis","volume":"60","author":"Lorbeer","year":"2020","journal-title":"Curr Opin Genet Dev."},{"issue":"7793","key":"2025021323425438200_CIT0026","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","article-title":"The evolutionary history of 2658 cancers","volume":"578","author":"Gerstung","year":"2020","journal-title":"Nature."},{"issue":"9","key":"2025021323425438200_CIT0027","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"13","key":"2025021323425438200_CIT0028","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1002\/cam4.2467","article-title":"Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer","volume":"8","author":"Panebianco","year":"2019","journal-title":"Cancer Med"},{"issue":"23","key":"2025021323425438200_CIT0029","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1002\/cncr.29038","article-title":"Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm\/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay","volume":"120","author":"Nikiforov","year":"2014","journal-title":"Cancer."},{"issue":"5","key":"2025021323425438200_CIT0030","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2025021323425438200_CIT0031","doi-asserted-by":"publisher","first-page":"979","DOI":"10.4158\/EP171805.RA","article-title":"Role of molecular markers in thyroid nodule management: then and now","volume":"23","author":"Nikiforov","year":"2017","journal-title":"Endocr Pract."},{"issue":"42","key":"2025021323425438200_CIT0032","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1038\/onc.2013.446","article-title":"The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene."},{"issue":"1","key":"2025021323425438200_CIT0033","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-19-0073","article-title":"Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology","volume":"181","author":"Censi","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2025021323425438200_CIT0034","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cyt.12492","article-title":"Molecular pathology and thyroid FNA","volume":"28","author":"Poller","year":"2017","journal-title":"Cytopathology."},{"issue":"10","key":"2025021323425438200_CIT0035","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/cancers11101443","article-title":"Clinical routine TERT promoter mutational screening of follicular thyroid tumors of uncertain malignant potential (FT-UMPs): a useful predictor of metastatic disease","volume":"11","author":"Hysek","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025021323425438200_CIT0036","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jasc.2020.03.004","article-title":"Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses","volume":"9","author":"Ohori","year":"2020","journal-title":"J Am Soc Cytopathol"},{"issue":"3","key":"2025021323425438200_CIT0037","doi-asserted-by":"publisher","first-page":"301","DOI":"10.21037\/gs.2019.04.11","article-title":"TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome","volume":"8","author":"Man","year":"2019","journal-title":"Gland Surg"},{"key":"2025021323425438200_CIT0038","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun."},{"issue":"19","key":"2025021323425438200_CIT0039","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/cncr.28800","article-title":"TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA","volume":"120","author":"Wang","year":"2014","journal-title":"Cancer."},{"issue":"6","key":"2025021323425438200_CIT0040","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1089\/thy.2017.0504","article-title":"TERT, HRAS, and EIF1AX mutations in a patient with follicular adenoma","volume":"28","author":"Topf","year":"2018","journal-title":"Thyroid."},{"key":"2025021323425438200_CIT0041","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun."},{"issue":"3","key":"2025021323425438200_CIT0042","doi-asserted-by":"publisher","first-page":"77.e17","DOI":"10.1016\/j.urolonc.2019.08.007","article-title":"Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer","volume":"38","author":"Roggisch","year":"2020","journal-title":"Urol Oncol."},{"issue":"5","key":"2025021323425438200_CIT0043","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/ERC-14-0359","article-title":"Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy","volume":"21","author":"Liu","year":"2014","journal-title":"Endocr Relat Cancer."},{"issue":"11","key":"2025021323425438200_CIT0044","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2025021323425438200_CIT0045","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/ERC-20-0435","article-title":"Molecular alterations in H\u00fcrthle cell nodules and preoperative cancer risk","volume":"28","author":"Doerfler","year":"2021","journal-title":"Endocr Relat Cancer."},{"issue":"7","key":"2025021323425438200_CIT0046","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00268-008-9484-1","article-title":"Do benign thyroid nodules have malignant potential? An evidence-based review","volume":"32","author":"Arora","year":"2008","journal-title":"World J Surg."},{"issue":"8","key":"2025021323425438200_CIT0047","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1158\/0008-5472.CAN-09-0024","article-title":"Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo","volume":"69","author":"Miller","year":"2009","journal-title":"Cancer Res."},{"issue":"11","key":"2025021323425438200_CIT0048","doi-asserted-by":"publisher","first-page":"E1852","DOI":"10.1210\/jc.2013-2292","article-title":"Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer","volume":"98","author":"Nikiforova","year":"2013","journal-title":"J Clin Endocrinol Metab."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/2\/251\/59066073\/aqae117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/2\/251\/59066073\/aqae117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T23:43:08Z","timestamp":1739490188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/163\/2\/251\/7754048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,9]]},"published-print":{"date-parts":[[2025,2,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqae117","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,9]]}}}